Clostridium novyi-NT (CNV-NT/BVD-550)
Solid Tumors
Phase 1Active
Key Facts
About BioMed Valley Discoveries
BioMed Valley Discoveries is a privately held, clinical-stage biotech with a novel operational and funding structure, wholly owned by a supporting organization of the non-profit Stowers Institute for Medical Research. This setup provides stable capital, allowing the company to pursue risk-tolerant, early-stage translational and clinical programs in oncology and other serious diseases. Its most advanced candidate is ulixertinib, a first-in-class ERK1/2 inhibitor, with a Phase 2 trial ongoing in histiocytosis and other MAPK-driven cancers. The company's strategy is to de-risk assets through clinical proof-of-concept and then partner them for later-stage development and commercialization.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| DM001 | Domabio | Phase 1 |
| DM002 | Domabio | Phase 1 |
| DM005 | Domabio | Phase 1 |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| CAR-T Solid Tumor Program | Carina Biotech | Phase 1/2a |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |